Pharming Group Q4 Earnings Call Highlights

Core Insights - Pharming Group reported strong financial performance for 2025, with significant revenue growth and a return to operating profitability, driven by its products RUCONEST and Joenja [6][5][4] Financial Performance - Total revenue for 2025 reached EUR 376.1 million, reflecting a 27% year-over-year increase, with fourth-quarter revenue of EUR 106.5 million, up 15% from the previous year [4][5] - Adjusted operating profit for 2025 was EUR 36.4 million, a turnaround from a loss of EUR 8.6 million in 2024, while operating cash flow improved to EUR 54.7 million [2][5] - Cash and marketable securities at year-end totaled EUR 181.1 million, despite EUR 68 million used for the Abliva acquisition [2] Product Performance - RUCONEST experienced a 26% year-over-year revenue growth in 2025, with a 9% increase in the fourth quarter, while Joenja's revenue grew 29% for the year and 53% in Q4 [1][4] - Joenja's global revenue for the fourth quarter was $19.8 million, with full-year revenue reaching $58 million, and the number of patients on paid therapy in the U.S. increased by 25% to 120 [9][10] Market Dynamics - The U.S. hereditary angioedema market is seeing new treatment options, but RUCONEST remains resilient, focusing on high-attack patients [7][8] - Pharming noted competitive impacts in Q4 as patients trialed new therapies, with some returning to RUCONEST, indicating a potential for patient switching back to the product [8] Future Guidance - For 2026, Pharming expects revenue growth of EUR 405 million to EUR 425 million, representing an 8% to 13% increase compared to 2025, driven by continued growth in RUCONEST and accelerated growth in Joenja [18] - Operating expenses for 2026 are projected to be between EUR 330 million and EUR 335 million, including over EUR 60 million in R&D investments [21] Pipeline and Regulatory Updates - Pharming is expanding Joenja beyond APDS into additional primary immunodeficiencies, with ongoing phase II trials expected to yield data in the second half of 2026 [13] - The company is addressing regulatory challenges for Joenja's pediatric label expansion and expects to align with the FDA on a resubmission path [15][16]